Navigation Links
YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS
Date:11/11/2009

a shareholders to vote on this transaction is scheduled to occur in January 2010.

    Nimotuzumab

    Nimotuzumab is currently being evaluated in 32 Phase II and III clinical
trials, 11 of which are being conducted by YM's majority owned subsidiary,
CIMYM BioSciences Inc., or its licensees.

    -   Daiichi Sankyo Co., Ltd., CIMYM's licensee for nimotuzumab in Japan,
        and YM's licensee in Korea, Kuhnil Pharmaceutical Co., are currently
        collaborating on a randomized, open-label Phase II trial evaluating
        nimotuzumab plus irinotecan compared to irinotecan alone in patients
        with advanced or recurrent gastric cancer refractory to 5-FU-
        containing regimens which is reportedly expected to complete
        recruitment in calendar 2009. Daiichi Sankyo is also conducting a
        Phase II trial in first-line NSCLC for which completion of
        recruitment is reportedly expected in the first half of 2010.

    -   YM initiated randomized, double-blind Phase II, trials in patients
        with brain metastases from non-small cell lung cancer (NSCLC) and in
        NSCLC patients ineligible for radical chemotherapy. Recruitment
        commenced in Canada in March 2009 for palliative NSCLC and in
        September for the brain metastases trial. A Phase II, second-line,
        single-arm trial in children with progressive diffuse intrinsic
        pontine glioma (DIPG) is ongoing at multiple sites in the US, Canada,
        and Israel.

    -   Oncoscience AG (OSAG), CIMYM's licensee for Europe, reported
        completion of recruitment in a single-arm, Phase III trial of
        nimotuzumab as first-line therapy for DIPG in August 2007, and the
        preliminary data from this trial that was released at ASCO in 2008
        was expanded on at the annual international pediatric oncology forum,
        SIOP, held in Sao Paulo, Brazil in October 2009. OSAG advises that,
        based on the data it plans to submit a Pediatr
'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Wash. , Dec. 24, 2014   BioLife Solutions , ... and marketer of proprietary clinical grade hypothermic storage ... shipping products for cells and tissues  ("BioLife" or the ... Meeting of Stockholders on May 4, 2015 (the "Annual Meeting"). ...
(Date:12/24/2014)... GMO corn cases filed across the United ... process of being consolidated in a Kansas federal court for ... MIR 162 Corn Litigation, MDL No. 2591 in the U.S. ... the Syngenta GMO corn multidistrict litigation (MDL) has been handed ...
(Date:12/24/2014)... MA (PRWEB) December 23, 2014 ... is designed to introduce cutting edge communication technology, ... of platform upgrades. This webinar series demonstrates online ... quest to leverage web conferencing’s most innovative and ...
(Date:12/24/2014)... 23, 2014 According to Ross Selinger, President ... of ITRA Global, the national office market continues to be ... This is evidenced by the third quarter’s surprising 3.9% GDP, ... Low energy costs have held inflation down and the Fed ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... CAMBRIDGE, Mass., May 21 Biopure Corporation,(Nasdaq: BPUR ... fiscal,quarter ended April 30, 2008. For the quarter, the ... per common share, compared with a net loss,of $6.2 ... period in,2007. Class A common shares outstanding on April ...
... Genetics,Inc. (Amex: ILI ), today expressed praise ... Nondiscrimination Act (GINA). The bill was approved,unanimously in ... into law by,President George W. Bush today., ... are protected,from genetic discrimination from employers and insurance ...
... The New Best Practice Statements Were Presented at ... YOKNEAM, Israel and PLYMOUTH MEETING, Pennsylvania, May ... cryotherapy, announced today that the,American Urological Association has ... cryotherapy. The guidelines state,that cryoablation is a treatment ...
Cached Biology Technology:Biopure Announces 2008 Second Quarter Financial Results 2Biopure Announces 2008 Second Quarter Financial Results 3Biopure Announces 2008 Second Quarter Financial Results 4Biopure Announces 2008 Second Quarter Financial Results 5Biopure Announces 2008 Second Quarter Financial Results 6Biopure Announces 2008 Second Quarter Financial Results 7Biopure Announces 2008 Second Quarter Financial Results 8Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA) 2Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA) 3American Urological Association (AUA) Clinical Guidelines Recognizes Cryotherapy as Treatment Option for Prostate Cancer Patients 2American Urological Association (AUA) Clinical Guidelines Recognizes Cryotherapy as Treatment Option for Prostate Cancer Patients 3
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally transforming the ... at international borders. Over the past decade, ePassports, biometric ... to self process through border control via eGates and ... of airports, seaports, and land borders across the globe. ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... 2015-2019"  report to their offering. One ... technology. With continuous advances in technology, it is important ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... brains are under intensive development all over the ... areas, according to a study just placed online. ... of Southern California chaired the eight-member committee which ... in Brain-Computer Interfaces," published in October by the ...
... Conn. A before-and-after study led by Yale biologists, ... genetic diversity of marine iguanas on the Galpagos Islands, ... the need to determine which environmental and biological factors ... to the authors, recurring El Nio events provide an ...
... Ossur, an emerging leader in the non-invasive orthopaedics ... is pleased to announce that the Journal of Trauma ... cervical collar study performed by the Mayo Clinic. The ... from Four Cervical Collars, finds that Ossurs products ...
Cached Biology News:Brain-computer link systems on the brink of breakthrough, study finds 2Global climate change: The impact of El Nio on Galpagos marine iguanas 2Mayo Clinic study: Ossur's collars superior in immobilization and reduction of pressure 2
... Clone/PAD: ZMD.414. Immunogen: Synthetic peptide ... mouse and rat mTOR (Mammalian target of ... for the human mTOR protein. On ... at ~235 kDa. Reactivity: Human (positive ...
...
From micro to giga sizes, from single prep to high-throughput, Invitrogen's range of plasmid purification kits offers superior performance to match the demands of your downstream application....
Request Info...
Biology Products: